LORELCO
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORELCO (probucol) is an oral small-molecule tablet approved in 1977 for cholesterol management. The drug's mechanism of action involves lipid-lowering properties, though it has largely been superseded by newer therapeutic options. It remains a legacy product with limited modern clinical use.
LOE Approaching
This legacy product faces significant competitive pressure (30/100) with minimal linked career opportunities, suggesting a small, mature team focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers
Started Mar 2009
120 enrolled
Chinese Healthy Volunteers
Career Relevance
Working on LORELCO offers minimal career growth opportunity; no active linked job postings reflect the product's legacy status and approaching end-of-life. Roles focus on compliance and market maintenance rather than strategic innovation.
Regulatory Affairs Specialist
Worked on LORELCO at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.